Does trastuzumab cause heart failure?

Does trastuzumab cause heart failure?

Symptomatic heart failure, a serious adverse effect of trastuzumab, occurs in 1% to 4% of patients treated with the antibody, whereas left ventricular ejection fraction declines substantially in 10% of patients. The prevalence of cardiotoxic effects of trastuzumab appears to increase with exposure to anthracyclines.

Does Herceptin cause heart problems?

Heart muscle damage and heart failure are potentially serious side effects of Herceptin. A small study has found that after 3 months of Herceptin treatment, nearly 58% of women had some loss of heart function. The study used heart ultrasounds (echocardiograms) to evaluate the women’s heart health.

What is the difference between Herceptin and trastuzumab?

Herceptin is the brand name of a medicine called trastuzumab. It’s used to treat some types of breast cancer, oesophageal cancer and stomach cancer.

How does Herceptin cause cardiotoxicity?

Cardiotoxicity of trastuzumab is considered to be the result of attenuated HER2-mediated signaling in the heart, culminating in decreased functionality of cardiac myocytes. HER2 appears to function as a compensatory mechanism acting against cardiac stress, such as anthracycline-induced cardiotoxicity.

Can Herceptin cause low heart rate?

But about one in four women treated with Herceptin develop heart problems, and some women must interrupt or stop the treatment if heart function declines too much. During Herceptin treatment, which is recommended for one year, toxicity can cause the heart to become too weak to pump blood.

Why does Herceptin cause cardiotoxicity?

Can Herceptin cause lung problems?

Lung problems Herceptin may cause inflammation of the lungs, which can be life-threatening. Symptoms include trouble breathing, cough, tiredness, and fluid in the lungs.

Is trastuzumab an immunotherapy?

Passive immunotherapy has provided several successful treatments for breast cancer. The current mainstay of passive immunotherapy includes trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).

How much does trastuzumab cost?

Results. Trastuzumab costs $49,915 and $28,350 per patient treated in the adjuvant and metastatic breast cancer settings, respectively; bevacizumab costs $48,490 and $39,614 per patient treated in the metastatic lung and colorectal cancer settings, respectively.